Principal Financial Group
XFOR icon

Principal Financial Group’s X4 Pharmaceuticals XFOR Stock Holding History

Principal Financial Group’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-457
Closed -$3.24K – 2329
2025
Q1 		$3.24K Sell
457
-26
-5% -$358 ﹤0.01% 2171
2024
Q4 		$10.6K Sell
483
-142
-23% -$2.26K ﹤0.01% 2203
2024
Q3 		$12.5K Sell
625
-422
-40% -$8.81K ﹤0.01% 2217
2024
Q2 		$18.2K Buy
1,047
+591
+130% +$19.3K ﹤0.01% 2344
2024
Q1 		$19K Sell
456
-98
-18% -$2.73K ﹤0.01% 2411
2023
Q4 		$13.9K Buy
554
+10
+2% +$243 ﹤0.01% 2397
2023
Q3 		$17.8K Buy
544
+84
+18% +$3.66K ﹤0.01% 2421
2023
Q2 		$26.8K Buy
+460
New +$23.6K ﹤0.01% 2401

Other funds holding XFOR

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Principal Financial Group's XFOR Position: Q2 2025 in Review

Principal Financial Group sold out of X4 Pharmaceuticals (XFOR) in Q2 2025, closing a stake of 457 shares — an estimated $3.24K sold.

Principal Financial Group first reported a position in XFOR in Q2 2023 and held it in 8 quarters. The position peaked at $26.8K in Q2 2023. 51 funds tracked by Wall St. Rank hold XFOR as of Q2 2025.

  • Principal Financial Group reported no remaining X4 Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Principal Financial Group sold 457 X4 Pharmaceuticals shares in Q2 2025, an estimated $3.24K.
  • Principal Financial Group first reported a position in X4 Pharmaceuticals in Q2 2023 and held it in 8 quarters.
  • Principal Financial Group's X4 Pharmaceuticals position peaked at $26.8K in Q2 2023.
  • 51 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q2 2025.

Based on Principal Financial Group's 13F filing for Q2 2025, filed 8 Aug 2025.